Company / Net Debt per Share
Theravance Biopharma, Inc. Net Debt per Share History
FY2017-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Debt per Share
-$0.61
FY2023
5-year range
-$0.61 / $8.18
FY2019-FY2023
Trend
-
vs FY2022
Sector context
#59 of 82
Health Care
What the data says
At $-0.61, Theravance Biopharma, Inc.'s net debt per share ranks #24 of 82 in the Health Care sector. Net Debt per Share has fluctuated over the past 6 years, ranging from $-0.61 in FY2023 to $9.43 in FY2020.
Based on SEC 10-K filings.
-0.61 in FY2023.
Improved from $9.43 to $-0.61 over the past 3 years.
Health Care sector context is included.
Net Debt per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#24 of 82 in Health CareTop 28% of 82This company -$0.61 Sector average $13.70
▼
-104.4% below sector average
Key checks
Key Insights
- Ranks #59 out of 82 companies in the Health Care sector.
- Peak net debt per share was recorded in FY2020.
Company context
Key Data Points
- Altman Z-Score -0.08 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net Debt per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | -$0.61 | - |
| FY2022 | - | - |
| FY2021 | $8.18 | -13.2% |
| FY2020 | $9.43 | +581.8% |
| FY2019 | $1.38 | -79.4% |
| FY2018 | $6.72 | +163.4% |
| FY2017 | $2.55 | - |
| FY2016 | - | - |
As of FY2023 · SEC 10-K · Updated Jun 30, 2026